Intervention Review

You have free access to this content

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events

  1. Christopher J Cates1,*,
  2. Roman Jaeschke2,
  3. Stefanie Schmidt3,
  4. Montse Ferrer3

Editorial Group: Cochrane Airways Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 1 AUG 2012

DOI: 10.1002/14651858.CD006922.pub3


How to Cite

Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD006922. DOI: 10.1002/14651858.CD006922.pub3.

Author Information

  1. 1

    St George's, University of London, Population Health Sciences and Education, London, UK

  2. 2

    McMaster University, Department of Medicine and Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada

  3. 3

    IMIM (Hospital del Mar Medical Research Institute), Health Services Research Unit, Barcelona, Spain

*Christopher J Cates, Population Health Sciences and Education, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. ccates@sgul.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 MAR 2013

SEARCH

[Figure 1]
Figure 1. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 2]
Figure 2. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids, outcome: 1.1 All cause mortality.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids, outcome: 1.2 All cause non-fatal SAE.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids, outcome: 1.3 Asthma-related SAE.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Regular salmeterol in addition to regular inhaled corticosteroids, outcome: 1.2 All cause non-fatal SAE.
[Figure 6]
Figure 6. Risk difference (per 10,000 patients) of asthma-related death by use of Inhaled corticosteroids in GSK meta-analysis of trials of regular salmeterol (from FDA submission 2008)
[Figure 7]
Figure 7. Risk difference (per 10,000 patients) of asthma-related hospitalisation by use of Inhaled corticosteroids in GSK meta-analysis of trials of regular salmeterol (from FDA submission 2008)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 1 All cause mortality.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 2 All cause non-fatal SAE.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 3 All cause SAE (fatal and non-fatal).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Regular salmeterol in addition to regular inhaled corticosteroids, Outcome 4 Asthma-related SAE.